Evoke Pharma, Inc. (EVOK)
- Previous Close
0.4750 - Open
0.4999 - Bid 0.3364 x 200
- Ask 0.6240 x 200
- Day's Range
0.4600 - 0.4999 - 52 Week Range
0.4100 - 2.1580 - Volume
16,557 - Avg. Volume
34,140 - Market Cap (intraday)
3.9M - Beta (5Y Monthly) 0.38
- PE Ratio (TTM)
-- - EPS (TTM)
-2.3300 - Earnings Date May 14, 2024 - May 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
www.evokepharma.com4
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: EVOK
Performance Overview: EVOK
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EVOK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EVOK
Valuation Measures
Market Cap
3.99M
Enterprise Value
4.25M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.30
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-150.41%
Return on Assets (ttm)
-49.09%
Return on Equity (ttm)
-1,035.44%
Revenue (ttm)
5.18M
Net Income Avi to Common (ttm)
-7.79M
Diluted EPS (ttm)
-2.3300
Balance Sheet and Cash Flow
Total Cash (mrq)
4.74M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.53M
Research Analysis: EVOK
Company Insights: EVOK
EVOK does not have Company Insights